GlassScriptPhysician profile
Hailey Brockman
NPI 1770967440
$5,281.44
in general payments reported to CMS, 2019-2025
27 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.71 · 2022: $4,069 · 2023: $447 · 2024: $506 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $3,966.79 | 2021-2025 | Envarsus |
| Aurinia Pharma U.S., INC. | $157.86 | 2023 | Lupkynis |
| Pharmacosmos Therapeutics INC. | $149.49 | 2024 | Monoferric |
| Calliditas Therapeutics US INC. | $134.98 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $108.80 | 2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $81.35 | 2022 | |
| La Jolla Pharmaceutical Company | $76.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.97 | 2023-2024 | Livtencity |
| Fresenius USA Marketing, INC. | $55.24 | 2022-2024 | Velphoro |
| Mallinckrodt Hospital Products INC. | $54.10 | 2024-2025 | Acthar |
| Vifor Pharma, INC. | $49.03 | 2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $41.40 | 2024-2025 | Jynarque, Abilify Asimtufii |
| Alexion Pharmaceuticals, INC. | $28.34 | 2021-2023 | Ultomiris |
| Amgen INC. | $28.20 | 2025 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $28.10 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.11 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $24.88 | 2025 | Invega Sustenna |
| Merck Sharp & Dohme LLC | $24.31 | 2024 | Prevymis |
| Ardelyx, INC. | $24.25 | 2024 | Ibsrela |
| Kci USA, INC. | $23.66 | 2023 | Activ.A.C., V.A.C. Veraflo Cleanse Choice, Prevena |
| Kyowa Kirin, INC. | $22.08 | 2024 | Crysvita |
| Travere Therapeutics, INC. | $20.85 | 2025 | |
| Axsome Therapeutics, INC. | $20.15 | 2025 | Auvelity |
| Renalytix Ai, INC. | $20.12 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.27 | 2025 | Givlaari |
| Jazz Pharmaceuticals INC. | $17.05 | 2025 | |
| Abbvie INC. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Brockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.